April 17, 2026 — In a move that underscores the accelerating consolidation of specialized antibody-drug conjugate (ADC) manufacturing capabilities, Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have announced a strategic collaboration designed to streamline the ADC development-to-commercialization pathway. The partnership pairs Piramal's two-decade track record as the world's first FDA-approved ADC contract manufacturer with Ajinomoto's proprietary AJICAP™ site-specific conjugation technology — creating a combined offering that addresses one of the most pressing bottlenecks in the ADC pipeline: efficient, scalable, and precise manufacturing.
The ADC market is experiencing explosive growth. With over 15 ADCs currently approved globally and more than 500 in various stages of clinical development, demand for specialized manufacturing capacity has outstripped supply. The global ADC market is projected to exceed $30 billion by 2030, driven by expanding indications in oncology, hematology, and beyond.
For API suppliers, intermediates manufacturers, and CDMO service providers, this growth represents a transformative opportunity — but also a formidable technical challenge. ADCs are among the most complex therapeutic molecules to manufacture, requiring expertise across three distinct domains: antibody production, cytotoxic payload synthesis, and the conjugation process that links them together. Each step demands specialized facilities, stringent quality controls, and deep technical know-how.
The Piramal-Ajinomoto collaboration directly addresses this complexity by offering customers a seamless, end-to-end pathway from conjugation technology selection through commercial-scale GMP manufacturing.
At the heart of this collaboration lies Ajinomoto's AJICAP™ platform, a set of proprietary technologies engineered for site-specific ADC conjugation. Unlike traditional stochastic conjugation methods — which randomly attach cytotoxic payloads to antibody residues, resulting in heterogeneous drug-antibody ratios (DARs) — AJICAP™ enables precise, site-directed payload attachment.
This precision translates into several critical advantages for drug developers:
Improved therapeutic index: Site-specific conjugation yields homogeneous ADC populations with optimized DARs, reducing off-target toxicity while maintaining or enhancing efficacy
Enhanced pharmacokinetics: Uniform conjugation sites lead to more predictable drug behavior in vivo, improving pharmacokinetic profiles and potentially widening the therapeutic window
Simplified manufacturing: AJICAP™'s efficient, well-characterized conjugation process reduces batch-to-batch variability and simplifies quality control, lowering manufacturing costs and timelines
Platform versatility: The technology supports a broad range of linker-payload combinations, enabling developers to tailor ADC constructs to specific target biology
Piramal Pharma Solutions brings unmatched commercial-scale ADC manufacturing credentials to this partnership. As the first CDMO to receive FDA approval for ADC manufacturing, Piramal has built a global network of state-of-the-art facilities spanning North America, Europe, and Asia.
The company's ADC track record is extensive: hundreds of ADCs developed, thousands of GMP batches completed, and multiple commercial-stage ADC programs currently in production. Piramal's facilities support the full spectrum of ADC manufacturing requirements — from small-scale clinical supply to large-scale commercial production — with dedicated suites for antibody processing, cytotoxic drug-linker manufacturing, conjugation, and fill-finish operations.
Under the collaboration, Piramal and Ajinomoto will execute a Material Transfer Agreement (MTA) enabling technology transfer between the two organizations. This will equip Piramal's personnel with the expertise and capabilities to manufacture AJICAP™-based ADC products with precision and speed, ensuring that customers leveraging Ajinomoto's conjugation technology have immediate access to proven GMP manufacturing capacity.
The Piramal-Ajinomoto alliance has significant implications for the broader API and pharmaceutical intermediates supply chain. As ADC programs proliferate, demand for specialized raw materials is surging across multiple categories:
Cytotoxic payloads: Highly potent compounds such as auristatins, maytansinoids, and camptothecin derivatives require specialized synthesis capabilities and containment infrastructure. The growing ADC pipeline is driving increased demand for GMP-grade payload manufacturing
Linker chemistry: Cleavable and non-cleavable linkers are critical ADC components, with the trend toward site-specific conjugation driving demand for more sophisticated linker architectures
Antibody intermediates: Cell line development, upstream bioprocessing, and downstream purification services are all in high demand as ADC developers scale from clinical to commercial production
Specialty chemicals and reagents: Conjugation-grade solvents, buffers, and analytical reference standards represent a growing niche within the ADC supply chain
For suppliers positioned in these segments, the Piramal-Ajinomoto collaboration signals continued demand growth and the importance of maintaining regulatory-grade manufacturing capabilities.
The Piramal-Ajinomoto partnership is the latest in a series of strategic moves by CDMOs to capture share in the rapidly expanding ADC manufacturing market. Recent developments include Lonza's expansion of its Visp, Switzerland, ADC facility; Samsung Biologics' investment in ADC capabilities; and Catalent's (now part of Novo Nordisk) continued expansion of its Bloomington, Indiana, conjugation facilities.
For pharmaceutical developers, the proliferation of capable ADC CDMOs is welcome news — reducing supply chain concentration risk and providing more options for technology-platform selection. However, the complexity of ADC manufacturing means that not all CDMOs are created equal, and partnerships like Piramal-Ajinomoto that combine specialized conjugation technology with proven commercial manufacturing experience offer a differentiated value proposition.
The Piramal-Ajinomoto collaboration represents a maturation of the ADC manufacturing ecosystem. As the industry moves from a handful of blockbuster ADCs toward a diverse pipeline of next-generation constructs — including bispecific ADCs, immune-stimulating ADCs, and dual-payload ADCs — the demand for flexible, technologically advanced manufacturing partnerships will only intensify.
For API suppliers and intermediates manufacturers, the key takeaway is clear: the ADC revolution is creating sustained, multi-layered demand across the pharmaceutical supply chain. Companies that invest in specialized capabilities for cytotoxic handling, linker-payload synthesis, and conjugation-grade materials will be well-positioned to capture this growing market.
As Peter DeYoung, CEO of Piramal Global Pharma, noted: "We are excited to collaborate with Ajinomoto Bio-Pharma Services and enhance our ADC platform by offering manufacturing support for AJICAP™-based products. With the implementation of these capabilities, we will accelerate innovation and expand access to this technology for our customers and their patients worldwide."
The ADC manufacturing race is on — and strategic alliances like this one are defining the competitive landscape for years to come.
